Vindesine
Trials 41 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 36 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00002887 Background | Jul 1995 → ? | lung cancer | Ottawa Regional Cancer Centre | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06739265 Background | Sep 2024 → Sep 2026 expected | peripheral T-cell lymphoma, not otherwise specified | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02987244 Background | Mar 2016 → Mar 2020 | T-cell non-Hodgkin lymphoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT07680933 Background | Mar 2026 → Jun 2027 expected | diffuse large B-cell lymphoma | The Affiliated Hospital of Xuzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06918015 Background | May 2025 → May 2028 expected | follicular lymphoma | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06674096 Background | Nov 2024 → Dec 2029 expected | diffuse large B-cell lymphoma | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06742515 Background | Oct 2024 → Oct 2026 expected | precursor B-cell acute lymphoblastic leukemia | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT05933967 Background | Jun 2023 → Dec 2024 overdue | — | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05498259 Background | Jul 2022 → Jan 2024 | diffuse large B-cell lymphoma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT05428670 Comparator | Jun 2022 → May 2025 | diffuse large B-cell lymphoma | First Affiliated Hospital of Wenzhou Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05290090 Background | Oct 2021 → Jun 2024 | diffuse large B-cell lymphoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04899570 Background | Apr 2021 → Apr 2023 | intravascular large B-cell lymphoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05049473 Background | Jan 2014 → Jan 2024 | Burkitt lymphoma | PETHEMA Foundation | Unknown | No outcome recorded |
| Phase 2 | NCT01173887 Comparator | Jul 2010 → Apr 2012 | adult T-cell leukemia/lymphoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00759824 Background | Sep 2008 → Dec 2013 | small cell lung carcinoma | European Lung Cancer Working Party | Completed | No outcome recorded |
| Phase 2 | NCT01458730 Background | May 2007 → Oct 2010 | central nervous system non-hodgkin lymphoma | University of Aarhus | Completed | No outcome recorded |
| Phase 2 | NCT01290120 Background | Nov 2002 → Jun 2014 | Burkitt lymphoma | Northern Italy Leukemia Group | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02871869 Background | Sep 2016 → Sep 2018 | diffuse large B-cell lymphoma | Xinjiang Medical University | Unknown | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT07004075 Comparator | Jun 2025 → Apr 2027 expected | childhood low-grade glioma, diffuse low-grade glioma, MAPK pathway–altered | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06361329 Comparator | Apr 2024 → Mar 2026 overdue | early T cell progenitor acute lymphoblastic leukemia | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 3 | NCT05681260 Background | Feb 2023 → Dec 2026 expected | T-lymphoblastic lymphoma | Children's Cancer Group, China | Recruiting | No outcome recorded |
| Phase 3 | NCT05164770 Comparator | Mar 2021 → Dec 2023 | high grade B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement, mantle cell lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03643276 Background | Jul 2018 → Jul 2028 expected | childhood acute lymphoblastic leukemia | Martin Schrappe | Recruiting | No outcome recorded |
| Phase 3 | NCT03206671 Background | Aug 2017 → Jun 2027 expected | B-cell non-Hodgkin lymphoma | University Hospital Muenster | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02867566 Background | Aug 2016 → Sep 2019 | diffuse large B-cell lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02881086 Background | Aug 2016 → Dec 2024 | acute lymphoblastic leukemia, lymphoblastic lymphoma | Goethe University | Completed | No outcome recorded |
| Phase 3 | NCT02767674 Comparator | May 2016 → Dec 2020 | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT01117441 Background | Jun 2010 → Dec 2021 | leukemia | University Hospital Schleswig-Holstein | Completed | No outcome recorded |
| Phase 3 | NCT03042429 Comparator | Jan 2007 → Dec 2016 | neuroblastoma | University of Cologne | Completed | No outcome recorded |
| Phase 3 | NCT00003728 Background | Dec 1998 → May 2008 | leukemia, lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT04152577 Background | Jun 2019 → Oct 2021 | B-cell non-Hodgkin lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03631862 Background | Sep 2018 → Dec 2019 | peripheral T-cell lymphoma, not otherwise specified | Zhengzhou University | Unknown | No outcome recorded |
| Phase 4 | NCT00199004 Background | Apr 2004 → Mar 2009 | adult acute lymphoblastic leukemia | Johann Wolfgang Goethe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00198991 Background | Apr 2003 → Jun 2011 | adult acute lymphoblastic leukemia | Goethe University | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05809180 Background | Jan 2023 → Jul 2025 | diffuse large B-cell lymphoma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| — | NCT05040555 Background | Aug 2021 → Sep 2023 overdue | diffuse large B-cell lymphoma | Ou Bai, MD/PHD | Recruiting | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 78 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vindesine | “Immunochemotherapy in Primary Central Nervous System Lymphoma With Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Ifosfamide, Vincristine, Vindesine, Temozolomide and DepoCyte...” NCT01458730 ↗75“Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide,...” NCT00554164 ↗ “Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1;...” NCT06176027 ↗ “Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin,...” NCT01290120 ↗ “cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid...” NCT05498259 ↗ “The induction therapy is a combination of Blinatumomab(Blina), Vindesine(VDS), Cyclophosphamide(CTX) and Dexamethasone(DXM).” NCT06742515 ↗ “The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.” NCT05933967 ↗ “(or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5.” NCT06674096 ↗ “4. Vindesine: 3 mg/m2 (maximum dose 4 mg) intravenously on days 1 of every cycle;” NCT06918015 ↗ “Vindesine: 3 mg/m²/day (max 4 mg), administered on days 1, 8, 15, 22.” NCT07059156 ↗ “CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)” NCT03631862 ↗ “VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)” NCT01173887 ↗ “cisplatin, vindesine, ifosfamide, dacarbacine, doxorubicine” NCT03042429 ↗ “such as vindesine 3 mg/m2, the maximum dose of 4mg” NCT06433362 ↗ “Vindesine: 4 mg, intravenous administration, Day 1” NCT07680933 ↗ “Vindesine 3 mg/m² (max 4 mg), intravenous, day 1” NCT07564453 ↗ “vincristine 1.4mg / m2 or vindesine 3mg / m2 d2” NCT04152577 ↗ “Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1” NCT05097443 ↗ “Vincristine 1.4mg/m2 or Vindesine 3mg/m2 d1” NCT05164770 ↗ “Vindesine Sulfate for Injection 4mg d1,8 iv” NCT04026269 ↗ “Vindesine: 4 mg, IV, day 2 of each cycle” NCT02867566 ↗ “vindesine (4 mg intravenously on day 1)” NCT06739265 ↗ “vindesine 3 mg/m² intravenously on d1” NCT00869284 ↗ “such as vindesine 2-3 mg/m2 on day 1” NCT06486337 ↗ “vindesine, 3mg/m², iv day 2” NCT05428670 ↗ “vindesine 2mg ivgtt d2;” NCT05809180 ↗ “Vindesine 3mg/ m2, D1” NCT05040555 ↗ “vindesine 3 mg/m2, d1” NCT05896813 ↗ “vindesine 4mg d1” NCT05290090 ↗ |
| Known as | COMPOUND 112531 | ChEMBL registry synonym — accepted as the source's own label CHEMBL238071 ↗ |
| Known as | DAVA | “vindesine (DAVA) IV on day 50” NCT00003728 ↗ |
| Known as | Eldisine | ChEMBL registry synonym — accepted as the source's own label CHEMBL238071 ↗ |
| Known as | Fildesin | ChEMBL registry synonym — accepted as the source's own label CHEMBL238071 ↗ |
| Known as | LY-099094 | ChEMBL registry synonym — accepted as the source's own label CHEMBL238071 ↗ |
| Known as | NSC-245467 | ChEMBL registry synonym — accepted as the source's own label CHEMBL238071 ↗ |
| Known as | VDS | “The induction therapy is a combination of Blinatumomab(Blina), Vindesine(VDS), Cyclophosphamide(CTX) and Dexamethasone(DXM).” NCT06742515 ↗ |
| Known as | Vindesina | ChEMBL registry synonym — accepted as the source's own label CHEMBL238071 ↗ |
| Known as | Vindesine Sulfate | “Vindesine Sulfate for Injection 4mg d1,8 iv” NCT04026269 ↗1“Drug: Vindesine Sulfate” NCT03206671 ↗ |
| Known as | Vindesine sulfate salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL238071 ↗ |
| Known as | Vindesine sulphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL238071 ↗ |
| Modality | Small molecule | — CHEMBL238071 ↗ |
| Route | Intravenous | “vindesine IV and daunorubicin IV on days 1, 8, and 15” NCT00002532 ↗ |